In a patient on cefuroxime who is taking Saccharomyces boulardii probiotic and yogurt, should she continue the probiotic as a preventive measure for Clostridioides difficile infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Should She Continue Saccharomyces boulardii While on Cefuroxime?

Yes, she should continue taking Saccharomyces boulardii while on cefuroxime for prevention of Clostridioides difficile infection. The 2020 AGA guidelines specifically recommend S. boulardii as one of the preferred probiotic strains for CDI prevention in adults and children receiving antibiotics 1.

Guideline-Based Recommendation

The American Gastroenterological Association (AGA) 2020 guidelines make a conditional recommendation (low quality evidence) suggesting the use of S. boulardii in adults and children on antibiotic treatment for prevention of C. difficile infection 1. This recommendation is based on:

  • A Cochrane review of 39 studies involving 9,955 patients showing probiotics reduced overall CDI risk (RR 0.40; 95% CI 0.30-0.52) 1
  • Subgroup analysis specifically showing S. boulardii reduced CDI risk (RR 0.41; 95% CI 0.22-0.79) 1
  • The benefit was primarily driven by patients at high risk for CDI, with no significant effect in low-risk patients 1

Supporting Real-World Evidence

Recent observational studies strengthen this recommendation:

  • A 2023 matched-cohort study found S. boulardii reduced hospital-onset CDI risk by 48% overall (aHR 0.52; 95% CI 0.31-0.87) 2
  • A 2021 retrospective study showed 43% risk reduction (OR 0.57; 95% CI 0.33-0.96) when S. boulardii was coadministered with high-risk antibiotics 3
  • Timing matters: Starting S. boulardii within 24 hours of antibiotic initiation showed greater benefit (OR 0.47; 95% CI 0.23-0.97) 3

Cefuroxime-Specific Considerations

While cefuroxime is not specifically mentioned in the studies, it belongs to the cephalosporin class, which is associated with CDI risk. The FDA label for cefuroxime explicitly warns: "Diarrhea is a common problem caused by antibiotics... patients can develop watery and bloody stools... even as late as 2 or more months after having taken the last dose" 4. This underscores the relevance of CDI prevention.

The 2023 study found particularly strong benefit with ceftriaxone (a related third-generation cephalosporin), showing 76% risk reduction with S. boulardii (aHR 0.24; 95% CI 0.11-0.53, NNT=100) 2. This suggests cephalosporins may be an ideal antibiotic class for targeted S. boulardii prophylaxis.

Important Caveats

Risk stratification matters: The AGA notes that patients at low baseline risk for CDI (particularly outpatients) may reasonably decline probiotics, especially if they place high value on avoiding cost or have concerns about potential harms 1. However, hospitalized patients, elderly patients, and those with multiple antibiotic exposures derive the most benefit.

One negative study exists: A 2012 single-center RCT in elderly hospitalized patients (mean age 79 years) found no benefit from S. boulardii for AAD or CDAD prevention 5. However, this contradicts the larger body of evidence and may reflect the specific frail elderly population studied.

Quality of evidence: The AGA downgraded evidence quality from moderate to low due to heterogeneity in study populations, antibiotic regimens, and risk of bias 1. Despite this, the consistency of benefit across multiple studies and the favorable safety profile support use.

Practical Implementation

  • Continue S. boulardii throughout the entire antibiotic course
  • Extend for 7 days after completing cefuroxime 5
  • Standard dosing: 250-500 mg (5-10 billion CFU) twice daily
  • Separate administration from antibiotic doses by 2-3 hours if possible (though not strictly necessary)
  • The yogurt she's eating provides additional benefit but is not a substitute for the specific S. boulardii strain

Safety Profile

S. boulardii is generally safe. The AGA notes that severely ill patients should weigh potential harms more carefully 1, but for most patients on oral cefuroxime (suggesting outpatient or moderate illness), the risk-benefit clearly favors continuation.

References

Related Questions

What is the recommended Florastor (Saccharomyces boulardii) dosing regimen for Clostridioides difficile infection?
What is the recommended dosing regimen for Florastor (Saccharomyces boulardii) in an adult patient taking antibiotics, including timing relative to the antibiotic doses and duration of therapy?
Do probiotics reduce the risk of Clostridioides difficile infection?
What evidence supports the efficacy of Florastor (Saccharomyces boulardii) in preventing antibiotic-associated diarrhea, recurrent Clostridioides difficile infection, and irritable bowel syndrome?
In an active runner with a prior episode of antibiotic‑associated diarrhea (possible Clostridioides difficile) who is now on day 3 of cefuroxime and experiencing loose stools, should the cefuroxime course be continued to the planned duration?
Does folinic acid improve speech in children with autism?
In Hashimoto's thyroiditis, does thyroid-stimulating hormone (TSH) remain elevated despite adequate levothyroxine replacement after the patient becomes hypothyroid?
What are the recommended strategies to regulate cerebral blood flow?
Why would thyroid-stimulating hormone (TSH) remain elevated in a patient with Hashimoto thyroiditis when free thyroxine (T4) and free triiodothyronine (T3) levels are normal?
Why is milky fluid observed in the ascitic drain after restarting tube feeding in a patient who underwent esophagectomy with a negative water‑soluble contrast study?
In a 56-year-old homeless male presenting with fever, cough, dyspnea, pleuritic chest pain, lower-lobe consolidation and an audible friction rub, what is the most appropriate pharmacologic agent?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.